Eli Lilly and Company (NYSE:LLY) Shares Sold by Ardevora Asset Management LLP

Ardevora Asset Management LLP lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 31.9% during the fourth quarter, Holdings Channel reports. The fund owned 23,952 shares of the company’s stock after selling 11,228 shares during the quarter. Eli Lilly and Company comprises 1.2% of Ardevora Asset Management LLP’s portfolio, making the stock its 23rd biggest holding. Ardevora Asset Management LLP’s holdings in Eli Lilly and Company were worth $13,962,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in LLY. Fairfield Bush & CO. acquired a new stake in shares of Eli Lilly and Company during the first quarter valued at $107,000. Roundview Capital LLC boosted its stake in Eli Lilly and Company by 2.6% in the 1st quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock worth $589,000 after buying an additional 53 shares during the last quarter. Merit Financial Group LLC acquired a new stake in Eli Lilly and Company in the 1st quarter worth about $210,000. NewEdge Advisors LLC boosted its stake in Eli Lilly and Company by 9.9% in the 1st quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock worth $15,193,000 after buying an additional 4,774 shares during the last quarter. Finally, Barometer Capital Management Inc. acquired a new stake in Eli Lilly and Company in the 1st quarter worth about $561,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the transaction, the insider now directly owns 99,488,598 shares of the company’s stock, valued at approximately $64,177,109,911.86. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

LLY has been the topic of a number of research analyst reports. Truist Financial reissued a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 22nd. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research note on Wednesday, February 21st. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. Barclays boosted their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Finally, Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Stock Down 2.6 %

NYSE LLY traded down $19.64 on Friday, reaching $726.31. The company had a trading volume of 3,505,526 shares, compared to its average volume of 2,202,924. The firm has a market capitalization of $690.11 billion, a PE ratio of 125.23, a P/E/G ratio of 1.58 and a beta of 0.34. Eli Lilly and Company has a 1 year low of $369.76 and a 1 year high of $800.78. The firm has a 50-day moving average of $763.96 and a 200-day moving average of $660.53. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period in the prior year, the company posted $2.09 EPS. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. On average, equities research analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.